Latest R&D Deal Builds China Antibody Interest, Expertise
This article was originally published in PharmAsia News
Executive Summary
To promote both the development of innovative therapeutic antibodies from research originating in China and technology transfer, the Institute Pasteur of Shanghai and MRC Technology are collaborating to speed antibody R&D and scouting licensing opportunities with local pharmas, adding to a string of deals indicative of China’s increasing expertise and interest in the sector.